Drug Trial Radar · NCT07858123
Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Jun 26, 2030
Study completion Jun 26, 2030
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CLI-05993AA5-06 study is an interventional study designed to investigate the safety and efficacy of a new experimental drug called CHF5993 pMDI compared to the currently approved Seretide 125 Evohaler pMDI in adolescent patients with uncontrolled asthma.
Conditions
- Asthma
Interventions
CHF5993 100/6/12.5 μg pMDI HFA-152aDrug
Drug: CHF5993 100/6/12.5 μg pMDI HFA-152a administered via Pressurized Metered Dose Inhaler (pMDI). Active ingredients: Beclomethasone Dipropionate (BDP)//Formoterol Fumarate (FF) /Glycopyrronium Bromide (GB) 100/6/12,5μg per actuation; Excipients: HFA-152a propellant.
Seretide EvohalerDrug
Drug: Seretide Evohaler administered via Pressurized Metered Dose Inhaler (pMDI). Active ingredients: Fluticasone Propionate (FP)/Salmeterol Xinafoate (SLM) pMDI 125/25μg per actuation; Excipients: HFA-134a propellant.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in pre-dose Forced Expiratory Volume FEV1 in the first second (FEV1).Time frame: Baseline (pre-dose on Week 0) and Week 26
Locations
25 sites in 3 countries. Site status is shown where the registry gives one.
Institute for Respiratory Diseases Medaimun GmbH
Frankfurt, Germany
Georg-August-Universität Göttingen
Göttingen, Germany
Universitätsklinikum Jena
Jena, Germany
Centre for Congenital Heart Defects Stuttgart, Paediatric Intensive Care, Pulmonology and Allergology
Stuttgart, Germany
ASST Spedali Civili Brescia
Brescia, Italy
"A. Perrino" Hospital
Brindisi, Italy
Istituto Giannina Gaslini Pediatric Allergic Center,
Genoa, Italy
University of Messina G. Martino Hospital, Allergy and Clinical Immunology Unit
Messina, Italy
Buzzi Children Hospital
Milan, Italy
Federico II University, Department of Translational Medical Sciences, Section of Pediatrics
Naples, Italy
IPAS (Respiratory Diseases of Pediatric Interest) University of Campania 'Luigi Vanvitelli',
Naples, Italy
University Hospital of Parma
Parma, Italy
University Hospital of Pisa, Pediatrics Unit
Pisa, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Woman and Child Health and Public Health
Roma, Italy
Bambino Gesù Pediatric Hospital IRCCS, Allergy Division
Rome, Italy
IRCCS Humanitas Research Hospital
Rozzano, Italy
Hospital Universitario Germans Trias
Badalona, Spain
Hospital Sant Joan de Deu
Barcelona, Spain
Vall d'Hebron University Hospital
Barcelona, Spain
Hospital General Universitario Santa Lucia
Cartagena, Spain
Hospital Universitario De Jerez Servicio de Pediatría
Jerez de la Frontera, Spain
Hospital Universitario Infanta Leonor
Madrid, Spain
Hospital Universitario Severo Ochoa
Madrid, Spain
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, Spain
IMED Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.